Feedback
Settings

Settings

Goto Application

5,834 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(UTAIYTHAJQNQDW-KQYNXXCUSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 584
1.WO/2025/240659ACTIVATABLE CONSTRUCTS, COMPOSITIONS AND METHODS
WO - 20.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/029426 Applicant CYTOMX THERAPEUTICS, INC. Inventor FOX, Ellaine Anne Mariano
Activatable constructs and methods of making and treating using the same, comprising a first antigen binding domain (AB1) having specific binding affinity for a first antigen, wherein the AB1 comprises a heavy chain variable domain 1 (HVD1) and a light chain variable domain 1 (LVD1), wherein the HVD1 is covalently coupled directly or indirectly to a first masking moiety (MM1) via a first cleavable moiety (CM1), wherein the LVD1 is covalently coupled directly or indirectly to a second masking moiety (MM2) via a second cleavable moiety (CM2), a second antigen binding domain (AB2) having specific binding affinity for a second antigen, wherein the AB2 comprises a heavy chain variable domain 2 (HVD2) and a light chain variable domain 2 (LVD2), a first dimerization domain (DD1) and a second dimerization domain (DD2).
2.WO/2025/240795END-MODIFIED GRNAS FOR IMPROVED BASE EDITING
WO - 20.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/029650 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor PERROTTA, Ramiro, Martin
Provided herein are compositions and methods for improving the editing efficiency and/or reducing the bystander editing of nucleobase editors, such as an adenine base editor (ABE). Some aspects of this disclosure describe sequence- specific anchor guide RNAs (agRNAs) with extended 3 '-nucleic acid extensions that improve the editing efficiency and/or reduce bystander editing of a nucleobase editor in a context dependent manner. Some aspects of the disclosure provide evolved nucleobase editors with narrowed editing windows and increased activity.
3.WO/2025/237619RIBOSOMAL RNA FRAGMENT METHYLATION PATTERN INDICATIVE FOR LUNG CANCER
WO - 20.11.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/EP2025/060456 Applicant HUMMINGBIRD DIAGNOSTICS GMBH Inventor RAJAKUMAR, Timothy
The present invention relates to a method for diagnosing lung cancer in a patient by determining the methylation status of a ribosomal RNA (rRNA) fragment.
4.WO/2025/240206MECHANISTIC MODEL FOR IMPROVING PRIME EDITING SYSTEMS, COMPOSITIONS, AND METHODS OF USING SAME
WO - 20.11.2025
Int.Class G16B 30/00
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
30ICT specially adapted for sequence analysis involving nucleotides or amino acids
 Appl.No PCT/US2025/028371 Applicant THE BROAD INSTITUTE, INC. Inventor LIU, David, R.
This disclosure includes methods and systems for improving prime editing systems (PES). Improvements include an improved method for selecting prime editing guide RNAs (pegRNA) and using these pegRNAs in PES systems to introduce a predetermined genetic change into a target genomic DNA.
5.WO/2025/240356LIPID NANOPARTICLES FOR HEPATIC DELIVERY
WO - 20.11.2025
Int.Class A61K 47/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
 Appl.No PCT/US2025/028962 Applicant RECODE THERAPEUTICS, INC. Inventor VENKATARAMAN, Guhan
Provided herein are lipid nanoparticles composition comprising a lipid component which comprises: (i) a first lipid wherein the first lipid is an ionizable cationic lipid, (ii) a second lipid wherein the second lipid is separate from the first lipid, (iii) a phospholipid, and (iv) a PEG-lipid wherein the second lipid is a lipid having a structural formula S-I'a, S-I'b, or S-I'c. Also, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering an effective amount of the lipid nanoparticle composition disclosed herein.
6.WO/2025/235876GASDERMIN D-CLEAVING PROTEASES AND USES THEREOF
WO - 13.11.2025
Int.Class C07K 14/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
33from Clostridium (G)
 Appl.No PCT/US2025/028625 Applicant THE BROAD INSTITUTE, INC. Inventor LIU, David, R.
Aspects of the disclosure relate to Botulinum toxin X (BoNT X) protein variants (e.g., BoNT X protease variants). The variants provided herein have been evolved to cleave gasdermin D. Some of the variants provided herein do not cleave the native substrate of BoNT X protease, VAMP1 protein. Further aspects of the disclosure relate to nucleic acids encoding the gasdermin D cleaving polypeptides described herein and expression vectors comprising the nucleic acids, as well as host cells and fusion proteins comprising the gasdermin D cleaving polypeptides described herein and kits comprising the gasdermin D cleaving polypeptides, nucleic acids, fusion proteins, expression vectors, or host cells described herein. Further aspects of the disclosure relate to methods of producing BoNT X protein variants (e.g., BoNT X protease variants) and methods of using the BoNT X protein variants (e.g., BoNT X protease variants), for example, to induce cell death.
7.WO/2025/231992SITE-SPECIFICALLY-MODIFIED ENGINEERED TRNA AND USE THEREOF
WO - 13.11.2025
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/CN2024/106308 Applicant PEKING UNIVERSITY Inventor XIA, Qing
A site-specifically-modified engineered tRNA and the use thereof. Said modification refers to replacement, with one or more modified nucleotides, of one or more native unmodified nucleotides selected from sites 4, 9, 13, 14, 17, 18, 27, 28, 32, 34, 35, 36, 37, 38, 39, 49, 50, 54, 55, 58 and 72 of a tRNA molecule. Compared with unmodified tRNAs, the site-specifically-modified tRNA has higher structural stability and/or higher nuclease degradation resistance, the aminoacylation efficiency thereof is not remarkably reduced, and immunogenicity thereof is not remarkably increased. The modified tRNA can be used for eliminating premature translation terminations caused by nonsense mutations, and thus has great application potentials in treating nonsense mutation-related genetic diseases, tumors, etc. The modification of the engineered tRNA also provides valuable insights for drug development of tRNAs and thus can guide the modification design of native tRNAs.
8.WO/2025/235563EPIGENETIC MODULATION FOR UPREGULATION OF GENES
WO - 13.11.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/US2025/028069 Applicant OMEGA THERAPEUTICS, INC. Inventor MORRISON-SMITH, Chevaun Danielle
The present disclosure is directed to compositions and methods for increasing expression of target genes in a cell, e.g., using an expression activator that comprises a targeting moiety that binds a target gene and an effector domain comprising an epigenetic activating domain. Systems comprising two or more expression activators are also disclosed.
9.WO/2025/233286THE USE OF ARCA AND 2'O-METHYL TRANSFERASE ENZYME TO PRODUCE CAP1 STRUCTURE OF 5' MRNA CAP
WO - 13.11.2025
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No PCT/EP2025/062232 Applicant THERMO FISHER SCIENTIFIC BALTICS UAB Inventor SLIKAS, Justinas
The invention refers to a method and a composition for synthesizing capped mRNA under conditions allowing for co-transcriptional mRNA capping and methylation of capped mRNA within the same reaction, thereby generating a synthesized capped mRNA, wherein the synthesized capped mRNA has a cap1-type structure.
10.20250340868POLYNUCLEOTIDES ENCODING LINKED ANTIGENS AND USES THEREOF
US - 06.11.2025
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No 18997630 Applicant STEMCELL TECHNOLOGIES CANADA INC. Inventor Scott McNabb Loughhead

The present disclosure provides isolated polynucleotides comprising multiple coding regions that are linked. In some aspects, a polynucleotide comprises at least a first coding region encoding a first antigen and a second coding region encoding a second antigen, wherein the first antigen and the second antigen are not the same, and wherein the first coding region and the second coding region are linked. The present disclosure also relates to the use of such polynucleotides to express multiple antigens in a cell and to induce multi-antigen-specific immune response in vivo.

# -